Mounjaro vs Ozempic
Released: Last reviewed: NexLife pricing verified: Updated:
Both for type 2 diabetes. Mounjaro (tirzepatide) demonstrates superior glycemic control and more weight loss (−11.2 kg on 15 mg vs −5.7 kg at 40 weeks) in the SURPASS-2 head-to-head trial vs Ozempic (semaglutide).
Mounjaro vs Ozempic — at a glance
| Mounjaro | Ozempic | |
|---|---|---|
| Active molecule | Tirzepatide | Semaglutide |
| Drug class | Dual GLP-1 / GIP agonist | GLP-1 agonist |
| Manufacturer | Eli Lilly | Novo Nordisk |
| FDA approved for | Type 2 diabetes | Type 2 diabetes; cardiovascular risk reduction in T2DM with CVD |
| Administration | Once-weekly SC injection | Once-weekly SC injection |
| Dose range | 2.5–15 mg weekly | 0.25–2 mg weekly |
| HbA1c reduction (head-to-head SURPASS-2) | −2.01 to −2.30% (5/10/15 mg) | −1.86% (1 mg) |
| Cardiovascular outcomes trial | SURPASS-CVOT ongoing | SUSTAIN-6 (positive); SELECT (positive in obesity) |
Different drugs, same family
Both are incretin therapies, but Mounjaro is a dual-agonist hitting both GLP-1 and GIP receptors, while Ozempic is a single GLP-1 agonist. The dual-agonist mechanism is associated with greater glucose and weight effects in head-to-head trials but with similar GI side-effect profiles.
Head-to-head efficacy
In SURPASS-2 (40 weeks, adults with T2DM), tirzepatide outperformed semaglutide 1 mg on both HbA1c reduction and weight loss. Note that semaglutide for obesity (Wegovy) uses higher doses (up to 2.4 mg weekly) than Ozempic for T2DM (up to 2 mg), and no head-to-head comparison of tirzepatide vs Wegovy 2.4 mg has been published as of 2026.
Cardiovascular evidence
Semaglutide has more mature cardiovascular outcome data: SUSTAIN-6 showed reduced cardiovascular events in T2DM, and SELECT (2023) showed reduced major adverse cardiovascular events in adults with obesity without diabetes. Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT / SURMOUNT-MMO) is ongoing as of 2026; tirzepatide currently does not carry an FDA-approved CV-risk-reduction indication.
Cost & access
Both list at approximately $1,000–$1,200/month before insurance. Both are widely covered for type 2 diabetes by commercial plans with prior auth. Compounded tirzepatide and compounded semaglutide are both available through telehealth providers at substantially lower cost; neither compounded version is FDA-approved.
Side effects
Both share the GLP-1 class side effects: nausea (most common), vomiting, diarrhea, constipation, abdominal pain, injection-site reactions. Both carry the thyroid C-cell tumor black-box warning. Both have a labeled risk of pancreatitis.
Frequently asked
Is Mounjaro better than Ozempic for diabetes?
In the SURPASS-2 head-to-head trial in adults with type 2 diabetes, tirzepatide (Mounjaro) produced greater HbA1c reduction and weight loss than semaglutide 1 mg (Ozempic) over 40 weeks. Cardiovascular outcomes data are more mature for semaglutide. Choice depends on clinical context.
Can I switch from Ozempic to Mounjaro?
Yes, with clinician supervision. Most clinicians restart titration from 2.5 mg tirzepatide weekly after a brief washout from the last semaglutide dose. Insurance prior authorization for the switch is the most common practical hurdle.
Which causes more side effects, Mounjaro or Ozempic?
Both share GLP-1 class side effects at similar rates. Some patients report greater nausea on tirzepatide (Mounjaro) at higher doses; others tolerate it better than semaglutide (Ozempic). Individual response varies; titration slowly is the standard mitigation.
NexLife Tirzepatide
Compounded semaglutide + tirzepatide · MD/DO oversight
*12-month plan · flat rate · all titration doses
- From $139/mo (12-mo plan)
- three named pharmacies
- MD/DO-supervised
- Care360 coaching included
- Provider oversight included
- LegitScript-certified
- Availability varies by state
Or call (949) 818-8000
Primary sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026)
- FDA: Policies for compounders as national GLP-1 supply stabilizes (updated April 1, 2026)
- FDA: Warning letters to 30 telehealth companies over compounded GLP-1 marketing (March 3, 2026)
- FDA: Compounding and the FDA — questions and answers
- FDA: Proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list (April 30, 2026)
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022